Survival
Survival Effect of Complete Multimodal Therapy in Malignant Pleural Mesothelioma
Journal of Chest Surgery 2022 September 7 [Link] Muhammet Sayan, Aynur Bas, Merve Satir Turk, Dilvin Ozkan, Ali Celik, İsmail Cuneyt Kurul, Abdullah Irfan Tastepe Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive pleural malignancy, and despite all multimodal treatment modalities, the 5-year overall survival rate of patients with MPM is less than 20%.…
Read MoreMeta-analysis of survival after extrapleural pneumonectomy (EPP) versus pleurectomy/decortication (P/D) for malignant pleural mesothelioma in the context of macroscopic complete resection (MCR)
Updates in Surgery 2022 September 3 [Link] Dimitrios E Magouliotis, Prokopis-Andreas Zotos, Arian Arjomandi Rad, Despoina Koukousaki, Vasiliki Vasilaki, Ioustini Portesi, Kyriakos Spiliopoulos, Thanos Athanasiou Abstract Objective: We reviewed the available literature on patients with MPM undergoing either extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D). Methods: Original research studies that evaluated long-term outcomes of P/D versus…
Read MoreIL-7 is expressed in malignant mesothelioma and has a prognostic value
Molecular Oncology 2022 August 28 [Link] Hoa-Le Mai, Sophie Deshayes, Thi-Van-Ha Nguyen, Virginie Dehame, Anne-Laure Chéné, Sophie Brouard, Christophe Blanquart Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer mainly related to asbestos exposure. Despite recent therapeutic advances, notably immunotherapies, the benefit remains limited and restricted to a small percentage of patients. Thus, a better…
Read MorePrognostic risk assessment model for alternative splicing events and splicing factors in malignant pleural mesothelioma
Cancer Medicine 2022 August 28 [Link] Yue Jiang, Chengda Zhang, Yang Chen, Shiyu Zhao, Yipeng He, Jun He Abstract Background: Malignant pleural mesothelioma (MPM) is a rare and highly malignant thoracic tumor. Although alternative splicing (AS) is associated with tumor prognosis, the prognostic significance of AS in MPM is unknown. Methods: Transcriptomic data, clinical information,…
Read MoreMicrobiomes, Epigenomics, Immune Response, and Splicing Signatures Interplay: Potential Use of Combination of Regulatory Pathways as Targets for Malignant Mesothelioma
International Journal of Molecular Sciences 2022 August 12 [Link] Botle Precious Setlai, Zilungile Lynette Mkhize-Kwitshana, Ravi Mehrotra, Thanyani Victor Mulaudzi, Zodwa Dlamini Abstract Malignant mesotheliomas (MM) are hard to treat malignancies with poor prognosis and high mortality rates. This cancer is highly misdiagnosed in Sub-Saharan African countries. According to literature, the incidence of MM is…
Read MoreA combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma
British Journal of Cancer 2022 August 23 [Link] Thinh T Nguyen, Hyun-Sung Lee, Bryan M Burt, Christopher I Amos, Chao Cheng Abstract Background: Malignant pleural mesothelioma (MPM) is a lung pleural cancer with very poor disease outcome. With limited curative MPM treatment available, it is vital to study prognostic biomarkers to categorise different patient risk…
Read MoreAn Examination of the Anti-Cancer Properties of Plant Cannabinoids in Preclinical Models of Mesothelioma
Cancers 2022 August 5 [Link] Emily K Colvin, Amanda L Hudson, Lyndsey L Anderson, Ramyashree Prasanna Kumar, Iain S McGregor, Viive M Howell, Jonathon C Arnold Abstract Mesothelioma is an aggressive cancer with limited treatment options and a poor prognosis. Phytocannabinoids possess anti-tumour and palliative properties in multiple cancers, however their effects in mesothelioma are…
Read MoreSingle-Center 20-Year Experience in Surgical Treatment of Malignant Pleural Mesothelioma
Journal of Clinical Medicine 2022 August 3 [Link] Giuseppe Mangiameli, Edoardo Bottoni, Umberto Cariboni, Giorgio Maria Ferraroli, Emanuela Morenghi, Veronica Maria Giudici, Emanuele Voulaz, Marco Alloisio, Alberto Testori Abstract Objectives: We examined a series of malignant pleural mesothelioma (MPM) patients who consecutively underwent surgery in our institution during the last 20 years. Across this period,…
Read MoreKAP1 is a new non-genetic vulnerability of malignant pleural mesothelioma (MPM)
NAR Cancer 2022 July 29 [Link] Eugenia Lorenzini, Federica Torricelli, Raffaella Zamponi, Benedetta Donati, Veronica Manicardi, Elisabetta Sauta, Italo Faria do Valle, Francesca Reggiani, Mila Gugnoni, Gloria Manzotti, Valentina Fragliasso, Emanuele Vitale, Simonetta Piana, Valentina Sancisi, Alessia Ciarrocchi Abstract Malignant pleural mesothelioma (MPM) is a rare and incurable cancer, which incidence is increasing in many…
Read MoreMolecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP
Targeted Oncology 2022 July [Link] Fatéméh Dubois, Céline Bazille, Jérôme Levallet, Elodie Maille, Solenn Brosseau, Jeannick Madelaine, Emmanuel Bergot, Gérard Zalcman, Guénaëlle Levallet Abstract Malignant pleural mesothelioma is a rare and aggressive neoplasm, which has primarily been attributed to the exposure to asbestos fibers (83% of cases); yet, despite a ban of using asbestos in…
Read More